American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Hybrid Conference
News, Events & Presentations

June 02, 2022 | Events

American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Hybrid Conference

Read More

June 01, 2022 | Events

Society of Investigative Dermatology (SID) Annual Meeting

Read More

May 25, 2022 | ~Home Feature| Press Release

Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline  

Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa

Read More

May 02, 2022 | Events

BIO International Convention

Read More

January 10, 2022 | ~Home Feature| Press Release

Castle Creek Biosciences Acquires Novavita Thera to Expand Innovative Cell and Gene Therapy Platform

Company adds in vivo capabilities to existing ex vivo approach for development of novel gene therapies

Read More

October 21, 2021 | ~Home Feature| Press Release

Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available

Read More

October 14, 2021 | Media Coverage

U.S. Food and Drug Administration Bulletin

FDA Awards 11 Grants to Clinical Trials to Develop New Medical Products for Rare Disease Treatments

Read More

September 29, 2021 | ~Home Feature| Press Release

Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments

Read More

April 20, 2021 | Press Release

Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer

Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial

Read More

October 28, 2020 | Press Release

Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of D-Fi Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area

Read More